Neural Regeneration Research ›› 2020, Vol. 15 ›› Issue (11): 1995-2007.doi: 10.4103/1673-5374.282238

Previous Articles     Next Articles

Should mast cells be considered therapeutic targets in multiple sclerosis?

Karen Henriette Pinke1, Sofia Fernanda Gonçalves Zorzella-Pezavento1, Vanessa Soares Lara2, Alexandrina Sartori1   

  1. 1 Institute of Biosciences, Department of Microbiology and Immunology, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil
    2 Bauru School of Dentistry, Department of Surgery, Stomatology, Pathology and Radiology, University of São Paulo, Bauru, São Paulo, Brazil
  • Online:2020-11-15 Published:2020-08-04
  • Contact: Karen Henriette Pinke, PhD,karen.pinke@gmail.com.
  • Supported by:
    This work was supported by São Paulo Research Foundation (FAPESP, grant Nos. 2015/03965-2 and 2014/00239-6), the National Council for Scientific and Technological Development (CNPq, grant Nos. 307603/2018-0 and 307269/2017-5), and Coordination for the Improvement of Higher Education Personnel (CAPES, Finance Code 001).

Abstract: Mast cells are immune cells of the myeloid lineage that are found throughout the body, including the central nervous system. They perform many functions associated with innate and specific immunity, angiogenesis, and vascular homeostasis. Moreover, they have been implicated in a series of pathologies (e.g., hypersensitivity reactions, tumors, and inflammatory disorders). In this review, we propose that this cell could be a relevant therapeutic target in multiple sclerosis, which is a central nervous system degenerative disease. To support this proposition, we describe the general biological properties of mast cells, their contribution to innate and specific immunity, and the participation of mast cells in the various stages of multiple sclerosis and experimental autoimmune encephalomyelitis development. The final part of this review is dedicated to an overview of the available mast cells immunomodulatory drugs and their activity on multiple sclerosis and experimental autoimmune encephalomyelitis, including our own experience related to the effect of ketotifen fumarate on experimental autoimmune encephalomyelitis evolution.

Key words: central nervous system, degenerative disease, experimental autoimmune encephalomyelitis, immunity, immunomodulatory drugs, inflammatory disease, ketotifen fumarate, mast cells, multiple sclerosis, therapeutic target